Inherited Risk Factor Found in One-Third of African Americans Multiple Myeloma Patients

Article

More than one-third of African American patients with monoclonal gammopathy of undetermined significance or multiple myeloma were found to have an inherited risk factor for the disease, according to the results of a European study.

More than one-third of African-American patients with monoclonal gammopathy of undetermined significance (MGUS) or multiple myeloma were found to have an inherited risk factor for the disease, according to the results of a European study.

“Since hyperphosphorylated paratarg-7 (pP-7) carrier state was shown to be the first molecularly defined autosomal-dominantly inherited risk factor for MGUS and multiple myeloma in a European population, the prevalence of pP-7 carrier state among African Americans who have a significantly higher incidence of MGUS/multiple myeloma is of interest,” wrote Michael Pfreundschuh, MD, of Saarland University Medical School in Homburg, Germany, and colleagues.

According to Pfreundschuh, because more than one-third of paraproteins in African-American patients with MGUS/multiple myeloma recognize pP-7 as an autoantigenic target, “this post-translationally modified autoantigen is the probable autoantigenic stimulus for the development of MGUS/multiple myeloma in these patients.”

Using isoelectric focusing and ELISA, Pfreundschuh and colleagues tested the prevalence of a pP-7 carrier state and the incidence of P-7–specific paraproteins in African American, European, and Asian patients with MGUS/multiple myeloma and healthy controls. They published their results in the International Journal of Cancer.

Of the patients with MGUS/multiple myeloma, 37% of African Americans had a paraprotein reacting with P-7 compared with 16.7% of Europeans (P < .001) and 4% of Japanese patients (P < .001). The difference between European and Japanese patients was also statistically significant.

Results showed that the prevalence of healthy pP-7 carriers was also greater among healthy African-Americans (11%) compared with healthy Europeans (1.5%; P < .001) and healthy Japanese (0.4%; P < .001) participants.

“It is surprising that such a high percentage of MGUS/multiple myeloma [cases] are probably initiated by a single (post-translationally) modified autoantigen,” Pfreundschuh told Cancer Network. “Since the hyperphosphorylated variant of paratarg-7 is inherited in an autosomal-dominant fashion, relatives of MGUS/multiple myeloma patients, with a paratarg-7–specific paraprotein at risk for MGUS/multiple myeloma, can be identified.”

The prevalence of pP-7 carriers was lower in all ethnic groups among healthy patients than among patients with MGUS/multiple myeloma. Therefore, healthy controls had an elevated risk for the condition among African American (odds ratio [OR] = 4.8; 95% confidence interval [CI], 2.2–10.3), European (OR = 13.6; 95% CI, 6.3–29.3), and Japanese (OR = 11.5; 95% CI, 1.4–94.1) controls.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content